Chagas disease, or American trypanosomiasis, is caused by the parasite Trypanosoma cruzi. Infection is most commonly acquired through contact with an infected triatomine bug (or "kissing bug," because it often bites the face). Infection can also occur from mother to baby (congenital), contaminated blood products (transfusions), or an organ transplanted from an infected donor. Chagas disease occurs mainly in Latin America, where an estimated 8 million to 11 million people are infected. People living in rural areas are at greatest risk. Most individuals with Chagas disease in the United States acquired their infections in other countries. Although there are triatomine bugs in the United States, only rare cases originating in the United States have been documented. The November 14, 2007, issue of JAMA includes an article about Chagas disease.
Grahic Jump Location
The acute infection phase lasts 2 to 3 months and is often mild; the chronic phase may be silent for many years. However, an estimated 30% of infected people will develop medical problems from Chagas disease over the course of their lives. Complications of chronic Chagas disease may include
heart rhythm abnormalities that can cause sudden death
dilated heart that doesn't pump blood well
dilated esophagus (tube leading from throat to stomach) or colon, leading to difficulties with eating or passing stool
For people who have suppressed immune systems (for example, due to AIDS or chemotherapy), Chagas disease can reactivate with parasites found in the circulating blood. This can potentially cause severe disease.
Medical history (including questions about travel and living conditions), physical examination, and an electrocardiogram are the first steps in determining whether an individual may have Chagas disease.
Blood tests
Chronic infection, affecting the heart or the intestinal system, may require specific tests of heart function or the condition of the esophagus or intestine.
Treatment for Chagas disease is recommended for all people diagnosed with an acute infection, congenital infection, and suppressed immune systems. Other chronically infected people (especially children, but also some adults) may also benefit from treatment. In the United States, medication for Chagas disease is available only through the Centers for Disease Control and Prevention. For questions regarding treatment, physicians can contact the Division of Parasitic Diseases at 770-488-7775. In Latin America, housing improvement and insecticide spraying have decreased the number of newly infected people and completely halted insect transmission in some areas. Screening of blood donations is another important public health tool in helping to prevent transfusion-acquired Chagas disease in Latin America and in the United States.
World Health Organizationhttp://www.who.int
Centers for Disease Control and Preventionhttp://www.cdc.gov/ncidod/dpd/parasites/chagasdisease
National Institute of Allergy and Infectious Diseaseshttp://www.niaid.nih.gov
To find this and previous JAMA Patient Pages, go to the Patient Page Index on JAMA's Web site at http://www.jama.com. Many are available in English and Spanish. A Patient Page on poverty and health was published in the October 24/31, 2007, issue.
Sources: World Health Organization, Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases
The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 203/259-8724.
TOPIC: INFECTIOUS DISEASES
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.